The molecular and behavioral changes in the long-term observations in mice model of Parkinson's disease

• Autorzy: Zaremba M. , Joniec L. , Piechal A. , Pyrzanowska J. , Kurkowska-Jastrzebska L. , Ciesielska A. , Czlonkowska A. , Czlonkowski A.
• Języki publikacji: EN

Abstrakty

EN

The pathogenesis of non-motor symptoms in Parkinson’s disease (PD) is complex and not fully understood, but is believed to be related to the widespread nature of dopaminergic dysfunction involving structures beyond the substantia nigra. Therefore we’ve also focused in our experiments on specifi c brain regions (e.g. hippocampus and prefrontal cortex) critically involved in spatial learning and memory processes. One year old C57/BL male mice received 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) 40 mg/kg, and control group received 0.9 % NaCl. To evaluate spatial learning and memory abilities, the Morris water maze (WM) behavioral test was provided after 6 months from the intoxication. The brain concentration of monoamines: dopamine (DA), noradrenaline (NA), 5 – hydroxytryptamine (5-HT) and amino acid: glutamate (Glu) were determined by using high – performance liquid chromatography (HPLC). Statistical signifi cances differences in monoamines levels between groups were noticed in hippocampus (NA, DA content) and prefrontal cortex (NA content). We didn’t notice signifi cant differences in the WM test parameters between MPTP and the control animals. Correlation between the results of the behavioral testing in the probe trial and the level of monoamines were calculated. Swim distance to reach the hidden platform was negatively correlated with NA level in the hippocampus (rp=−0.62, P<0.05). There is need for a further investigation to confi rm the role for NA in spatial memories.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2009
• Tom: 69
• Numer: 3
• Opis fizyczny: p.345

Twórcy

autor

Zaremba M.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Joniec L.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Piechal A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Pyrzanowska J.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland

autor

Kurkowska-Jastrzebska L.

• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Ciesielska A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Czlonkowska A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland
• Second Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland

autor

Czlonkowski A.

• Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland